skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
p38 MAPK Inhibitor LY3007113 (Code C99134)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: p38 MAPK Inhibitor LY3007113

Definition: An orally active p38 mitogen-activated protein kinase (MAPK) inhibitor with potential immunomodulating, anti-inflammatory, and antineoplastic activity. Upon administration, LY3007113 inhibits the activity of p38, thereby preventing p38 MAPK-mediated signaling. This may result in the inhibition of the production of proinflammatory cytokines and the induction of tumor cell apoptosis. p38 MAPK, a serine/threonine protein kinase often upregulated in cancer cells, plays a crucial part in the production of a variety of cytokines involved in inflammation and cellular proliferation such as tumor necrosis factor (TNF) and interleukin (IL)-1 and -6.

Display Name: p38 MAPK Inhibitor LY3007113

Label: p38 MAPK Inhibitor LY3007113

NCI Thesaurus Code: C99134 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL432952  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
LY3007113
p38 MAPK Inhibitor LY3007113

External Source Codes: 
PDQ Closed Trial Search ID 716106
PDQ Open Trial Search ID 716106 (check for NCI PDQ open clinical trial info)
NCI META CUI CL432952

Other Properties:
     Name Value (qualifiers indented underneath)
code C99134
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99134

Mainbox Bottom